Renzapride (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Renzapride" in English language version.

refsWebsite

Global rank English rank

8nih.gov

4^th place

7doi.org

2^nd place

4semanticscholar.org

11^th place

8^th place

2web.archive.org

1^st place

1healio.com

low place

1businessweekly.co.uk

low place

1hal.science

low place

businessweekly.co.uk

Quested T (26 June 2019). "Atlantic Healthcare pounces on big bucks US opportunity". Business Weekly. Archived from the original on 1 July 2019. Retrieved 12 July 2019.

doi.org

Meyers NL, Hickling RI (2008). "Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome". Drugs in R&D. 9 (1): 37–63. doi:10.2165/00126839-200809010-00004. PMC 7044400. PMID 18095752.
Camilleri M, McKinzie S, Fox J, Foxx-Orenstein A, Burton D, Thomforde G, et al. (October 2004). "Effect of renzapride on transit in constipation-predominant irritable bowel syndrome". Clinical Gastroenterology and Hepatology. 2 (10): 895–904. doi:10.1016/s1542-3565(04)00391-x. PMID 15476153.
Mackie AD, Ferrington C, Cowan S, Merrick MV, Baird JD, Palmer KR (April 1991). "The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis". Alimentary Pharmacology & Therapeutics. 5 (2): 135–142. doi:10.1111/j.1365-2036.1991.tb00014.x. PMID 1888816. S2CID 20428833.
Tack J, Middleton SJ, Horne MC, Piessevaux H, Bloor JS, Meyers NL, Palmer RM (June 2006). "Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome". Alimentary Pharmacology & Therapeutics. 23 (11): 1655–1665. doi:10.1111/j.1365-2036.2006.02940.x. PMID 16696817. S2CID 25481560.
George AM, Meyers NL, Hickling RI (May 2008). "Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting". Alimentary Pharmacology & Therapeutics. 27 (9): 830–837. doi:10.1111/j.1365-2036.2008.03649.x. PMID 18284648. S2CID 38167889.
Lembo AJ, Cremonini F, Meyers N, Hickling R (May 2010). "Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study". Alimentary Pharmacology & Therapeutics. 31 (9): 979–990. doi:10.1111/j.1365-2036.2010.04265.x. PMID 20163375.
Ford AC (July 2010). "Renzapride in IBS: is efficacy in the eye of the beholder?". Alimentary Pharmacology & Therapeutics. 32 (1): 113–114. doi:10.1111/j.1365-2036.2010.04275.x. PMID 20597877. S2CID 28565520.

hal.science

Ford AC (July 2010). "Renzapride in IBS: is efficacy in the eye of the beholder?". Alimentary Pharmacology & Therapeutics. 32 (1): 113–114. doi:10.1111/j.1365-2036.2010.04275.x. PMID 20597877. S2CID 28565520.

healio.com

"FDA accepts cardiac safety trial for gastroparesis drug". Healio. 21 May 2018. Archived from the original on 12 July 2019. Retrieved 12 July 2019.

nih.gov

pubmed.ncbi.nlm.nih.gov

Meyers NL, Hickling RI (2008). "Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome". Drugs in R&D. 9 (1): 37–63. doi:10.2165/00126839-200809010-00004. PMC 7044400. PMID 18095752.
Camilleri M, McKinzie S, Fox J, Foxx-Orenstein A, Burton D, Thomforde G, et al. (October 2004). "Effect of renzapride on transit in constipation-predominant irritable bowel syndrome". Clinical Gastroenterology and Hepatology. 2 (10): 895–904. doi:10.1016/s1542-3565(04)00391-x. PMID 15476153.
Mackie AD, Ferrington C, Cowan S, Merrick MV, Baird JD, Palmer KR (April 1991). "The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis". Alimentary Pharmacology & Therapeutics. 5 (2): 135–142. doi:10.1111/j.1365-2036.1991.tb00014.x. PMID 1888816. S2CID 20428833.
Tack J, Middleton SJ, Horne MC, Piessevaux H, Bloor JS, Meyers NL, Palmer RM (June 2006). "Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome". Alimentary Pharmacology & Therapeutics. 23 (11): 1655–1665. doi:10.1111/j.1365-2036.2006.02940.x. PMID 16696817. S2CID 25481560.
George AM, Meyers NL, Hickling RI (May 2008). "Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting". Alimentary Pharmacology & Therapeutics. 27 (9): 830–837. doi:10.1111/j.1365-2036.2008.03649.x. PMID 18284648. S2CID 38167889.
Lembo AJ, Cremonini F, Meyers N, Hickling R (May 2010). "Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study". Alimentary Pharmacology & Therapeutics. 31 (9): 979–990. doi:10.1111/j.1365-2036.2010.04265.x. PMID 20163375.
Ford AC (July 2010). "Renzapride in IBS: is efficacy in the eye of the beholder?". Alimentary Pharmacology & Therapeutics. 32 (1): 113–114. doi:10.1111/j.1365-2036.2010.04275.x. PMID 20597877. S2CID 28565520.

ncbi.nlm.nih.gov

Meyers NL, Hickling RI (2008). "Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome". Drugs in R&D. 9 (1): 37–63. doi:10.2165/00126839-200809010-00004. PMC 7044400. PMID 18095752.

semanticscholar.org

api.semanticscholar.org

Mackie AD, Ferrington C, Cowan S, Merrick MV, Baird JD, Palmer KR (April 1991). "The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis". Alimentary Pharmacology & Therapeutics. 5 (2): 135–142. doi:10.1111/j.1365-2036.1991.tb00014.x. PMID 1888816. S2CID 20428833.
Tack J, Middleton SJ, Horne MC, Piessevaux H, Bloor JS, Meyers NL, Palmer RM (June 2006). "Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome". Alimentary Pharmacology & Therapeutics. 23 (11): 1655–1665. doi:10.1111/j.1365-2036.2006.02940.x. PMID 16696817. S2CID 25481560.
George AM, Meyers NL, Hickling RI (May 2008). "Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting". Alimentary Pharmacology & Therapeutics. 27 (9): 830–837. doi:10.1111/j.1365-2036.2008.03649.x. PMID 18284648. S2CID 38167889.
Ford AC (July 2010). "Renzapride in IBS: is efficacy in the eye of the beholder?". Alimentary Pharmacology & Therapeutics. 32 (1): 113–114. doi:10.1111/j.1365-2036.2010.04275.x. PMID 20597877. S2CID 28565520.

web.archive.org

"FDA accepts cardiac safety trial for gastroparesis drug". Healio. 21 May 2018. Archived from the original on 12 July 2019. Retrieved 12 July 2019.
Quested T (26 June 2019). "Atlantic Healthcare pounces on big bucks US opportunity". Business Weekly. Archived from the original on 1 July 2019. Retrieved 12 July 2019.